What does CND Life Sciences do?
CND Life Sciences develops advanced diagnostic tools for neurodegenerative diseases. Its flagship product, the Syn-One Test, is the first commercially available skin-based diagnostic that visualizes and quantifies abnormal alpha-synuclein, aiding in the diagnosis of conditions like Parkinson’s disease, dementia with Lewy bodies, and more.
How much did they raise?
The company raised $13.5M in a Series A3 round led by VILAS Ventures, with participation from investors such as Cambrian Capital Partners, Tanis Ventures, Lupo Labs, Top Corner Capital, HonorHealth, Triana, Gold Bench Capital, BlueStone Ventures, Labcorp, and MBX Capital.
What are their plans for the money?
CND Life Sciences plans to use the funds to accelerate its commercial growth and R&D initiatives, aiming to expand access to its Syn-One Test. This investment is expected to significantly enhance the availability and impact of diagnostic solutions for neurodegenerative conditions.
What have they achieved so far?
The company has already demonstrated strong market traction by launching its CLIA-certified and CAP-accredited Syn-One Test, processing over 35,000 tests, and achieving adoption by nearly 3,000 neurologists across the U.S.
